Abstract:K-Ras is the most commonly mutated oncogene in human cancer, yet direct small-molecule targeting of K-Ras mutants has been mostly unsuccessful until recently. The discovery of an allosteric pocket under Switch-II with covalent cysteine-crosslinking molecules has allowed for the development of targeted therapies that selectively engage the highly reactive acquired cysteine in the K-Ras(G12C) mutation without affecting the wild-type protein. Sotorasib and adagrasib, two advanced Switch-II Pocket inhibitors, have received FDA approval to treat K-Ras(G12C)-driven non-small cell lung cancer. However, the most frequent K-Ras mutation G12D particularly prevalent in pancreatic ductal adenocarcinoma has remained untargetable with covalent drugs due to the poor nucleophilicity of the somatic aspartate residue. Here we present a set of malolactone-based electrophiles which exploit ring strain to crosslink K-Ras(G12D) at the mutant aspartate to form stable covalent complexes. Structural insights from x-ray crystallography and exploitation of the stereoelectronic requirements for attack of the electrophile allowed development of a substituted malolactone which resisted attack by aqueous buffer but rapidly crosslink with the aspartate-12 of K-Ras in both GDP- and GTP-state. The signaling-competent GTP-state targeting allowed effective suppression of downstream signaling and proliferation of cancer cells harboring K-Ras(G12D) mutation, and tumor growth of cell line-derive xenograft in mice. Our results demonstrate the rational design of covalent inhibitors to target a non-catalytic carboxylic acid side chain in K-Ras(G12D) which has resisted traditional drug discovery efforts. ### Competing Interest Statement K.M.S., Z.Z., and Q.Z. are inventors on patents related to covalent K-Ras(G12D) inhibitors reported here. K.M.S. is an inventor on patents owned by University of California San Francisco covering KRAS targeting small molecules licensed to Araxes, Erasca and Novartis. K.M.S. has consulting agreements for the following companies, which involve monetary and/or stock compensation: Revolution Medicines, Black Diamond Therapeutics, BridGene Biosciences, Denali Therapeutics, Dice Molecules, eFFECTOR Therapeutics, Erasca, Novartis, Genentech/Roche, Janssen Pharmaceuticals, Kumquat Biosciences, Kura Oncology, Mitokinin, Type6 Therapeutics, Nested Therapeutics, Vevo, Wellspring Biosciences (Araxes Pharma), Ikena, Initial Therapeutics and BioTheryX.

Simultaneous Covalent Modification of K-Ras(G12D) and K-Ras(G12C) with Tunable Oxirane Electrophiles

A New Dawn for Targeted Cancer Therapy: Small Molecule Covalent Binding Inhibitor Targeting K-Ras (G12C)

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

Covalent inhibitor targets KRasG12C: A new paradigm for drugging the undruggable and challenges ahead

Strain-release alkylation of Asp12 enables mutant selective GTP-state targeting of K-Ras(G12D)

Abstract B102: Development of covalent inhibitors targeting Ras Q61 hotspot mutants

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with alpha-Substituent Electrophiles Targeting Cysteine

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with -Substituent Electrophiles Targeting Cysteine

Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy

Abstract C099: Mutant-selective, covalent inhibitors of K-Ras(G12D)

Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways

KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge

Discovery of Novel Noncovalent KRAS G12D Inhibitors through Structure-Based Virtual Screening and Molecular Dynamics Simulations

Computer-aided drug design of some KRAS G12C inhibitors: Targeting the covalent and allosteric binding site for cancer therapy

Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS G12D

Reversible Small Molecule pan-Ras Inhibitors Display Tunable Affinity for the Active and Inactive forms of Ras.

Design, Synthesis, and Evaluation of 4(1H)-Quinolinone and Urea Derivatives As KRASG12C Inhibitors with Potent Antitumor Activity Against KRAS-mutant Non-Small Cell Lung Cancer.

Strain-release alkylation of Asp12 enables mutant selective targeting of K-Ras-G12D

Design, Synthesis, and Pharmacological Evaluation of Multisubstituted Pyrido[4,3- d ]pyrimidine Analogues Bearing Deuterated Methylene Linkers as Potent KRAS G12D Inhibitors

Research Progress on Small Molecule Inhibitors Targeting KRAS G12C with Acrylamide Structure and the Strategies for Solving KRAS Inhibitor Resistance

Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRASG12C inhibitors